文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

液体活检与非小细胞肺癌：我们是否初见端倪？

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

机构信息

Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

出版信息

Br J Cancer. 2022 Aug;127(3):383-393. doi: 10.1038/s41416-022-01777-8. Epub 2022 Mar 9.

DOI:10.1038/s41416-022-01777-8
PMID:35264788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9345955/
Abstract

The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one of the main achievements of translational research in the latest years. In the modern clinical management of advanced non-small cell lung cancer, molecular characterisation plays an essential role. In parallel, immunotherapy is widely employed, but reliable predictive markers are not available yet. Liquid biopsy has the potential to face the two issues and to increase its role in advanced NSCLC in the next future. The aim of this review is to summarise the main clinical applications of liquid biopsy in advanced non-small cell lung cancer, underlining both its potential and limitations from a clinically driven perspective.

摘要

肿瘤在血液中释放的遗传物质的分析可能性无疑是近年来转化研究的主要成果之一。在晚期非小细胞肺癌的现代临床管理中，分子特征起着至关重要的作用。与此同时，免疫疗法也得到了广泛应用，但目前还没有可靠的预测标志物。液体活检有可能解决这两个问题，并在未来增加其在晚期非小细胞肺癌中的作用。本文的目的是总结液体活检在晚期非小细胞肺癌中的主要临床应用，从临床驱动的角度强调其潜力和局限性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/a0b7ad0b0908/41416_2022_1777_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/540041651826/41416_2022_1777_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/d3b2691f58ea/41416_2022_1777_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/a0b7ad0b0908/41416_2022_1777_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/540041651826/41416_2022_1777_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/d3b2691f58ea/41416_2022_1777_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9345955/a0b7ad0b0908/41416_2022_1777_Fig3_HTML.jpg

相似文献

[1]
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

Br J Cancer. 2022-8

[2]
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.

Lung Cancer. 2017-5

[3]
The evolving role of liquid biopsy in lung cancer.

Lung Cancer. 2022-10

[4]
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

J Thorac Oncol. 2018-6-6

[5]
Is tissue still the issue in detecting molecular alterations in lung cancer?

Respirology. 2020-9

[6]
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.

Expert Rev Mol Diagn. 2021-11

[7]
Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.

Cells. 2021-7-28

[8]
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.

Cytopathology. 2018-12

[9]
Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies.

Biochim Biophys Acta Rev Cancer. 2022-5

[10]
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.

Curr Oncol Rep. 2018-7-20

引用本文的文献

[1]
A case of EGFR-positive lung adenocarcinoma that once transformed into small cell carcinoma but worsened into adenocarcinoma again.

Respir Med Case Rep. 2025-7-22

[2]
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions.

JCO Precis Oncol. 2025-6

[3]
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257).

J Exp Clin Cancer Res. 2025-6-19

[4]
The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer.

Lancet Reg Health West Pac. 2025-6-5

[5]
Identification of Driver Mutations and Risk Stratification in Lung Adenocarcinoma via Liquid Biopsy.

Cancers (Basel). 2025-4-16

[6]
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers.

J Liq Biopsy. 2024-2-10

[7]
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the Gene.

Cancers (Basel). 2025-2-7

[8]
A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

J Exp Clin Cancer Res. 2025-2-12

[9]
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer.

NPJ Precis Oncol. 2024-10-17

[10]
Circular RNAs in human diseases.

MedComm (2020). 2024-9-4

本文引用的文献

[1]
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.

Nat Cancer. 2020-9

[2]
Divergent - and -Mediated Resistance to Osimertinib in -Mutant NSCLC: A Case Report.

JCO Precis Oncol. 2021-11

[3]
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.

Ann Transl Med. 2021-6

[4]
Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.

Cancer Sci. 2021-10

[5]
Acquired Resistance to KRAS Inhibition in Cancer.

N Engl J Med. 2021-6-24

[6]
Sotorasib for Lung Cancers with p.G12C Mutation.

N Engl J Med. 2021-6-24

[7]
Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.

Transl Lung Cancer Res. 2021-4

[8]
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.

ESMO Open. 2021-6

[9]
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.

Cancers (Basel). 2021-4-19

[10]
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.

Transl Lung Cancer Res. 2021-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索